▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #3438 by analyst upside · 2026-06-27
WST
West Pharmaceutical Services, Inc.
Healthcare · Market Cap $25B · P/E 46.3x
ANALYST PRICE TARGET
+2.3%
implied upside to consensus target
Current Price $350.85
Consensus Target $358.79
Bull Target $400.0
Bear Target $310.0
Analysts Covering 14
ANALYST CONSENSUS — BUY
Strong Buy
2
Buy
9
Hold
3
Sell
0
52-Week Low $206.8
52-Week High $352.31
YTD Return +27.1%
FUNDAMENTALS
Market Cap $25B
P/E Ratio (TTM) 46.3x
Forward P/E 36.7x
EPS (TTM) $7.58
PEG Ratio 3.28
Dividend Yield 0.25%
Revenue (TTM) $3.2B
Profit Margin 16.8%
52-WEEK RANGE
52-Week Low $206.8
52-Week High $352.31
Current Price $350.85
Bear Target $310.0
Bull Target $400.0
● Now $350.85 ● Target $358.79
TRADING DATA
Avg Volume 849K
YTD Return +27.1%
Analyst Count 14
Consensus Buy
Upside to Target +2.3%
Last Updated 2026-06-27

ANALYST SUMMARY

West Pharmaceutical Services, Inc. (WST) is currently trading at $350.85 with a Wall Street consensus price target of $358.79, implying potential upside of 2.3% over the next 12 months. 14 analysts currently cover WST, with a consensus rating of Buy — 79% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $400.0, while the most cautious has a target of $310.0.

WST operates in the Healthcare sector with a market capitalisation of $25B. The stock is up 27.1% year-to-date and is currently trading near the upper end of its 52-week range of $206.8 – $352.31.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

MTD +3.8%
Mettler-Toledo International Inc.
$26B · P/E 29.2x · Buy
DGX +6.5%
Quest Diagnostics Incorporated
$23B · P/E 22.8x · Buy
ILMN -15.1%
Illumina, Inc.
$27B · P/E 32.3x · Hold
LH +14.2%
Labcorp Holdings Inc.
$22B · P/E 23.6x · Buy
DXCM +21.5%
DexCom, Inc.
$27B · P/E 30.1x · Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for WST, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Barclays ↑ Upgrade
Equal-Weight → Overweight 2026-06-09 Building track record
Stephens & Co. reit
Overweight → Overweight 2026-06-02 Building track record
Morgan Stanley — Reiterated
Equal-Weight → Equal-Weight 2026-05-29 Building track record
Barclays — Reiterated
Equal-Weight → Equal-Weight 2026-04-27 Building track record
Barclays — Reiterated
Equal-Weight → Equal-Weight 2026-04-14 Building track record
Barclays — Reiterated
Equal-Weight → Equal-Weight 2026-02-13 Building track record
Evercore ISI Group — Reiterated
Outperform → Outperform 2026-02-03 Building track record
Morgan Stanley ● Initiated
Equal-Weight 2025-12-02 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
—
out of 100
Coverage depth
0/30
Consensus clarity
0/30
Vote unanimity
0/25
Rating stability
0/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call — not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →